Brain Cancer Clinical Trials in Los Angeles

Showing 41-60 of 136 trials

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

NCT05563272

A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.

Cervical CancerColorectal CancerEsophageal Cancer+16 more

Telix Pharmaceuticals (Innovations) Pty Ltd11 participantsStarted Jun 2023

Los Angeles, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +7 more locations

Active Not RecruitingPhase 2/3< 1 mile

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

NCT05685004

This randomized study is designed to compare the combination of TVI-Brain-1 immunotherapy and standard therapy compared to standard therapy alone as a treatment for newly diagnosed MGMT unmethylated glioblastoma patients. The patients' own cancer cells collected after surgery are combined into a vaccine to produce an immune response that significantly increases the number of cancer neoantigen-specific effector T cell precursors in the patient's body. These cancer neoantigen-specific T cells are harvested from the blood, subsequently stimulated and expanded, and infused back into the patient.

Glioblastoma Multiforme of Brain

TVAX Biomedical120 participantsStarted Sep 2023

Tucson, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +5 more locations

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Brain Cancer Trials in Other Cities

VB-111 in Surgically Accessible Recurrent/Progressive GBM

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Other Conditions in Los Angeles